Emerging Companies

Jaguar to deploy $139M series B toward broad gene therapy pipeline

Less than two months after emerging from stealth, Jaguar raised a $139 million series B co-led by Lilly and Deerfield that will further facilitate translation of its executives’ experience developing SMA...

Crossovers Fidelity, Surveyor invest early in ValenzaBio, backing $70M series A for rare autoimmune play

With a $70 million series A round led by Fidelity in a syndicate that included crossover Surveyor, start-up ValenzaBio is readying to take antibodies licensed from CRUK and Pierre Fabre into early clinical...

VCs led by HBM, Samsara back single-asset Mitsubishi Tanabe spinout Mineralys with $40M for hypertension program

A VC syndicate led by HBM and Samsara will supply newly launched Mineralys with $40 million in series A funding to run a Phase II trial of an aldosterone synthase inhibitor to treat hypertension, giving...

Alloy: Building a better toolbox for biologics developers

Four-year-old Alloy is acting on its vision to become an infrastructure partner to biologic drug developers by collecting an arsenal of tools and resources, starting with an in-licensed transgenic mouse platform for antibody discovery. Founded...

Entrada: Moving cell-penetrating DMD therapy into clinic with $116M series B

With $116 million to deploy from its new series B crossover round, Entrada has concluded that DMD is its top priority among many potential applications of its platform for delivering biologics to intracellular targets. Founded...

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

Cross-border company AffaMed now has more than $170 million in series B funding and the backing of Lake Bleu Capital to pair with its hiring of one of China’s most prominent dealmakers, Ji Li,...

Asher Bio: aiming cytokine therapies at specific immune cells

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...

Dunad: Expanding protein degradation beyond E3 ligase

Dunad has emerged from a year in stealth with a platform that the U.K. company believes could offer a simpler mechanism for degrading protein targets.  One of the primary differentiating features...

Blackfynn: optimizing trial design for neurodegenerative therapies

Blackfynn has pivoted from a data service company to a drug developer that in-licenses clinical assets for neurodegenerative disease, starting with a Phase III-ready program for Parkinson’s. Blackfynn Inc. uses its platform to integrate existing...

Through Aktis, MPM bets on radiotherapy for solid tumors

Aktis believes the pharmacology of its solid tumor-targeting α-emitters will differentiate the MPM Capital-founded newco from the growing wave of targeted radiotherapy companies. President and CEO Matthew Roden told BioCentury the company originated from MPM’s...

AgomAb: antibodies driving tissue regeneration and recovery

AgomAb parlayed what began as a cancer drug discovery partnership into an antibody program that could drive tissue regeneration and organ recovery.  On Wednesday, the Belgian biotech raised $74 million in a series B round...

Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella

Ventyx is the second start-up in the past month to bundle asset-centric companies under one umbrella with an eye towards advancing each program faster than the originator companies could have had they...

Proxygen’s knockout take on targeted protein degradation

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash. Founded last May, Proxygen GmbH has raised seed funding from the Austrian government...

Araris: universal linkers for antibody-drug conjugates

Araris is developing antibody-drug conjugate linker technology that could widen the therapeutic window for ADCs by improving their stability and solubility. In addition, the Swiss biotech’s peptide linkers...

Orna: turning circular RNAs into therapies

Orna emerged from stealth Wednesday with an $80 million A round to develop circular RNA therapies for cancer and genetic diseases that could be easier to manufacture than linear RNAs and immune cell therapies. MPM Capital,...